|
Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of recombinant alpha 1-antitrypsin (rAAT) for hereditary emphysema.
Arriva Pharmaceuticals BV is headquartered in Amsterdam, the Netherlands, and its majority-owned subsidiary, Arriva Pharmaceuticals, Inc., is located in Alameda, California. Investors in Arriva are Nordic Biotech and MPM BioVentures.
|
